Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Naoe

Showing results (271-280 of 288) with videos related to

Pageof 29
Sort By:
Annals of Hematology|September 4, 2020
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemiaHitoshi Minamiguchi, Hiroyuki Fujita, Yoshiko Atsuta, et al.
International Journal of Clinical Oncology|August 7, 2021
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemiaNaoko Hosono, Hisayuki Yokoyama, Nobuyuki Aotsuka, et al.
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
Leukemia Research|January 24, 2018
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 studyYasuhiko Harada, Yasunobu Nagata, Rika Kihara, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Nature Genetics|March 29, 2016
Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adultsTakahiko Yasuda, Shinobu Tsuzuki, Masahito Kawazu, et al.
Cancers|June 5, 2020
Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the LiteratureAkihiro Takeshita, Norio Asou, Yoshiko Atsuta, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 2, 2006
[Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan]Shuichi Miyawaki, Nobuhiko Emi, Kinuko Mitani, et al.
Blood Advances|January 4, 2020
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
Pageof 29

Showing results (271-280 of 288) with videos related to

Sort By:
Pageof 29
Annals of Hematology|September 4, 2020
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemiaHitoshi Minamiguchi, Hiroyuki Fujita, Yoshiko Atsuta, et al.
International Journal of Clinical Oncology|August 7, 2021
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemiaNaoko Hosono, Hisayuki Yokoyama, Nobuyuki Aotsuka, et al.
Blood|August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyEunice S Wang, Pau Montesinos, Mark D Minden, et al.
Leukemia Research|January 24, 2018
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 studyYasuhiko Harada, Yasunobu Nagata, Rika Kihara, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Nature Genetics|March 29, 2016
Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adultsTakahiko Yasuda, Shinobu Tsuzuki, Masahito Kawazu, et al.
Cancers|June 5, 2020
Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the LiteratureAkihiro Takeshita, Norio Asou, Yoshiko Atsuta, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 2, 2006
[Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan]Shuichi Miyawaki, Nobuhiko Emi, Kinuko Mitani, et al.
Blood Advances|January 4, 2020
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
Pageof 29